Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal (Q38098484)

28 August 2017

Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal (English)

1 reference

28 August 2017

1 reference

1

Ben Kearns

1 reference

28 August 2017

Myfanwy Lloyd Jones

2

1 reference

PubMed ID

23580356

28 August 2017

Matt Stevenson

series ordinal

3

1 reference

PubMed ID

23580356

28 August 2017

Chris Littlewood

series ordinal

4

1 reference

28 August 2017

1 June 2013

1 reference

28 August 2017

1 reference

28 August 2017

31

1 reference

28 August 2017

6

1 reference

28 August 2017

479-488

1 reference

https://scigraph.springernature.com/pub.10.1007/s40273-013-0050-9

28 August 2017

0 references

cites work

TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0050-9

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23580356

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23580356

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23580356

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40273-013-0050-9

1 reference

28 August 2017

1 reference

PubMed ID

23580356